Heterodimeric Fc-fused proteins

US11787864B2 · kind B2 · utility

Assignee

• Dragonfly Therapeutics, Inc. · US

Inventors

• Ann F. Cheung · Lincoln, US
• Jean-Marie Cuillerot · Somerville, US
• Asya Grinberg · Lexington, US
• Eva Gutierrez · Illertissen, DE
• William Haney · Wayland, US
• Nicolai Wagtmann · Concord, US

Key dates

• Filing date: Sep 1, 2022
• Grant date: Oct 17, 2023
• Expiry date: Sep 1, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides Fc-fused protein constructs, which as monovalent dimers have a higher serum half-life compared to a native/natural molecule, and are, therefore, advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are Fc-fused protein constructs having mutations in the Fc region that reduce effector functions, which have increased activity to inhibit tumor growth and are, therefore, advantageous when used as a cancer therapy.